TNF and myeloid sarcoma: Puerarin was able to dose-dependently reduce the phosphorylation of ERK, the expression of TNF-α and NOS3, and the release of TNF-α and NO to inhibit inflammatory signaling in RAW264.7 macrophages treated with high concentrations of free fatty acids, which are often increased in patients with T2DM and MS [67].